Dong-A ST Completes Patient Enrollment for Global Phase 3 Clinical Trial of Psoriasis Treatment

[Asia Economy Reporter Minji Lee] Dong-A ST announced on the 19th that patient enrollment for the global Phase 3 clinical trial of the chronic plaque psoriasis treatment DMB-3115 has been completed. The patient enrollment countries include Poland and eight other countries.

The company stated, "This is to evaluate the efficacy, safety, and immunogenicity of DMB-3115, a biosimilar of Stelara," adding, "Stelara is the original biologic drug approved for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis."